- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03437070
Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
A Phase I Study of Trabectedin in Combination With Fixed Doses of Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a traditional 3+3 phase I trial design to identify the recommended phase II dose (RP2D) of Trabectedin [T] that can be used in combination with Doxorubicin [D] and Olaratumab [O] for the treatment of patients with advanced stage or recurrent LMS.
Patients will be treated at an assigned dose level of combination therapy per dose escalation design.
Study Type
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed metastatic, advanced, or recurrent, LMS. Note: Patients should have tissue, either archival or fresh biopsy, submitted for pathologic review to confirm diagnosis of LMS. For patients with recurrent disease with disease free interval greater than six months, a fresh biopsy must be obtained.
All patients with recurrent or metastatic LMS deemed unresectable must have measurable disease as defined by RECIST 1.1.
All patients with advanced LMS may be enrolled after an initial cytoreductive surgery if there is measurable disease as defined by RECIST 1.1.
- Life expectancy greater than 3 months.
- Male or female, age ≥18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1.
- Resolution of clinically significant toxic effects of prior surgery, radiotherapy or systemic anticancer therapy.
- Patients must not have received prior doxorubicin chemotherapy; only 1 prior chemotherapy line allowable and must be discontinued at least 4 weeks prior to first day of study treatment.
- Patients should be free of active infections requiring antibiotics (with exception of urinary tract infection).
Patients must have adequate organ and marrow function as defined below: Absolute neutrophil count (ANC) ≥1,500 cells/mm³
- Platelet count ≥100,000/mm³
- Hemoglobin ≥9.0g/dL
- Total bilirubin <1.0 upper limit of normal (ULN)
- Alkaline phosphatase of non-osseous origin ≤ 2.5 x ULN
- Aminotransferase (AST and ALT) ≤ 2.5 x ULN
- Creatinine phosphokinase (CPK) ≤ 2.5 x ULN
- Isotope Dilution Mass Spectrometry (IDMS) creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 40 mL/min
- Albumin ≤ 3 g/dL*
- *Hypoalbuminemia < 3 g/dL should be considered carefully but in and of itself, not exclusionary.
- Women of child-bearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation until 3 months for women and 5 months for men after completion of study drug administration. WOCBP must have a negative serum or urine test at time of enrollment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study therapy, and 5 months after completion of study drug administration.
- Patients must have adequate cardiac function (ejection fraction ≥ 45%) to receive therapy.
- Ability to understand the investigational nature, potential risks and benefits of the research study and to provide valid written informed consent.
Exclusion Criteria:
- Patients without histologically confirmed LMS
- Patients without measurable disease by RECIST 1.1 criteria
- Prior doxorubicin, trabectedin, or olaratumab chemotherapy
- Patients with an ECOG of 2, 3 or 4 (Appendix C)
- Patient with known allergies to pegfilgrastim/filgrastim.
- Patients with known active central nervous system (CNS) metastasis and/or carcinomatous meningitis.
- Use of other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of study therapy and during the study.
- Patients with a known sensitivity to humanized antibodies or sensitivity attributed to compounds of similar chemical or biological composition to alkylating agents or anthracyclines.
- A QT interval corrected for heart rate using the Bazett's formula (QTcB) ≥ 480 msec.
- Patients on combination antiretroviral therapy are ineligible.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infections (including viral hepatitis), decompensated cirrhosis or chronic liver disease, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements.
- Adults unable to consent, pregnant or nursing women or prisoners.
- Any serious medical or psychiatric illness/condition likely in the judgment of the Investigator(s) to interfere or limit compliance with study requirements/treatment.
- Diagnosis of another primary malignancy within the past 5 years with the exception of non-melanoma skin cancer.
- Patients with a prior history of grade 3 capillary leak syndrome (CLS) or <grade 3 CLS with pulmonary involvement.
- Unwilling to abstain from alcohol ingestion for duration of the study
- Patients with elevated liver function or bilirubin not meeting criteria for treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TDO Dose Level
Trabectedin [T], Doxorubicin [D], and Olaratumab [O]
|
Administered intravenously per protocol on Day 1 for 21-day cycles.
Other Names:
Administered intravenously per protocol on Day 1 for 21-day cycles.
Other Names:
Administered intravenously per protocol
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recommended Phase 2 Dose (RP2D) of Trabectedin in Combination with Doxorubucin and Olaratumab
Time Frame: About 21 days, one cycle of protocol therapy
|
Determination of the recommended phase 2 dose (RP2D) of Trabectedin [T] to be used in combination with Doxorubicin [D] and Olaratumab [O] for the treatment of patients with metastatic or recurrent LMS.
Patients will be treated at one of 4-6 dose levels according to the standard dose escalation/de-escalation scheme.
In accordance with this scheme, the RP2D of TDO will be established as the highest dose level tested for which no more than 2 out of 12 patients experiences dose-limiting toxicity (DLT).
|
About 21 days, one cycle of protocol therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity in Study Participants
Time Frame: Up to 8 months
|
Determination of the safety, tolerability, and toxicity profile of administering TDO in metastatic or recurrent LMS patients, including assessment of dose-limiting toxicities (DLTs).
|
Up to 8 months
|
Clinical Benefit Rate in Study Participants
Time Frame: From Baseline to End of Treatment, up to 8 months
|
Clinical benefit rate (CBR), as defined by best response, (Complete Response (CR), Partial Response (PR) or Stable Disease (SD)) will be assessed using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1.
|
From Baseline to End of Treatment, up to 8 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Sarcoma
- Neoplasms, Muscle Tissue
- Leiomyosarcoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Doxorubicin
- Liposomal doxorubicin
- Trabectedin
- Olaratumab
Other Study ID Numbers
- 20170991
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leiomyosarcoma
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingLocally Advanced Leiomyosarcoma | Metastatic Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Leiomyosarcoma | Uterine Corpus LeiomyosarcomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Uterine Corpus LeiomyosarcomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Leiomyosarcoma | Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IIIC Uterine Corpus Leiomyosarcoma... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingLocally Advanced Uterine Corpus Leiomyosarcoma | Metastatic Uterine Corpus Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Uterine Corpus LeiomyosarcomaUnited States, Puerto Rico
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedUterus Leiomyosarcoma | Soft Tissue LeiomyosarcomaFrance
-
National Cancer Institute (NCI)Active, not recruitingStage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Uterine Corpus LeiomyosarcomaUnited States
-
Kristen GanjooRecruitingUterine Leiomyosarcoma | LMS - LeiomyosarcomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); EMD SeronoTerminatedMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Liposarcoma | Unresectable LiposarcomaUnited States
-
David Liebner, MDWithdrawnLocally Advanced Leiomyosarcoma | Metastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Stage III Retroperitoneal Sarcoma AJCC v8 | Stage IIIA Retroperitoneal Sarcoma AJCC v8 | Stage IIIB Retroperitoneal Sarcoma AJCC v8 | Stage IV Retroperitoneal Sarcoma AJCC v8United States
-
Gachon University Gil Medical CenterMerck KGaA, Darmstadt, Germany; Chong Kun Dang Pharmaceutical Corp.RecruitingLeiomyosarcoma MetastaticKorea, Republic of
Clinical Trials on Trabectedin
-
Italian Sarcoma GroupAstraZeneca; PharmaMarActive, not recruitingAdvanced Soft Tissue SarcomaItaly
-
Italian Sarcoma GroupPharmaMarWithdrawnLeiomyosarcoma | Liposarcoma | Synovial SarcomaItaly
-
PharmaMar, SpainCompletedSoft Tissue SarcomaGermany
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Completed
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedSarcomaUnited States
-
European Organisation for Research and Treatment...CompletedSarcoma | Small Intestine Cancer | Ovarian Cancer | Brain and Central Nervous System Tumors | Endometrial Cancer | Gastrointestinal Stromal Tumor
-
European Organisation for Research and Treatment...CompletedUnspecified Adult Solid Tumor, Protocol SpecificFrance, Spain, Denmark, Netherlands, Norway, Belgium, United Kingdom, Israel, Italy, Switzerland, Germany, Austria, Greece, Portugal
-
University of Colorado, DenverWithdrawn
-
PharmaMarCompletedRelapsed Ovarian CancerSpain, France, Italy, Belgium, Germany
-
Grupo Español de Investigación en Cáncer de OvarioCompleted